TS
Thomas Shrader BTIG Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
|
DRUG
1
Bright Minds Biosciences
DRUG
$299M
| $42.24 | $72 |
70%
upside
| Buy |
8 Sep ‘25
5 hours ago |
|
2
Gain Therapeutics
GANX
$63.3M
| $1.76 | $9 |
411%
upside
| Buy |
8 Sep ‘25
5 hours ago |
|
3
AC Immune
ACIU
$229M
| $2.28 | $8 |
251%
upside
| Buy |
8 Sep ‘25
5 hours ago |
|
4
Biohaven
BHVN
$1.68B
| $15.87 | $60 |
278%
upside
| Buy |
19 Aug ‘25
20 days ago |
|
5
Harrow
HROW
$1.37B
| $36.99 | $63 |
70%
upside
| Buy |
14 Aug ‘25
25 days ago |
|
6
Aldeyra Therapeutics
ALDX
$334M
| $5.56 | $9 |
62%
upside
| Buy |
7 Apr ‘25
5 months ago |
|
7
Ovid Therapeutics
OVID
$87.5M
| $1.23 | $4 |
225%
upside
| Buy |
24 Mar ‘25
5 months ago |
|
8
Vaxcyte
PCVX
$4.29B
| $33.02 | $160 |
385%
upside
| Buy |
24 Feb ‘25
6 months ago |
|
9
Arcturus Therapeutics
ARCT
$485M
| $17.85 | $41 |
130%
upside
| Buy |
28 Jan ‘25
7 months ago |
|
10
Alector
ALEC
$305M
| $3.01 | $5 |
66%
upside
| Buy |
26 Nov ‘24
9 months ago |
|
11
ProMIS Neurosciences
PMN
$22.3M
| $0.4300 | $8 |
1,760%
upside
| Buy |
3 Oct ‘23
1 year ago |
|
12
Precision BioSciences
DTIL
$59.8M
| $5.07 | $60 |
1,083%
upside
| Buy |
28 Jul ‘23
2 years ago |
|
13
Annexon
ANNX
$238M
| $2.17 | $7 |
223%
upside
| Buy |
25 May ‘23
2 years ago |
|
14
Coya Therapeutics
COYA
$105M
| $6.27 | $15 |
139%
upside
| Buy |
18 May ‘23
2 years ago |
|
15
BioAtla
BCAB
$31.5M
| $0.5365 | $13 |
2,323%
upside
| Buy |
28 Mar ‘23
2 years ago |
|
16
Acumen Pharmaceuticals
ABOS
$87.2M
| $1.44 | $22 |
1,428%
upside
| Buy |
5 Oct ‘22
2 years ago |
|
17
Pliant Therapeutics
PLRX
$114M
| $1.86 | $51 |
2,642%
upside
| Buy |
20 Apr ‘21
4 years ago |
|
18
Celularity
CELU
$64.3M
| $2.41 | $16 |
564%
upside
| Buy |
26 Mar ‘21
4 years ago |
|
19
Nuvation Bio
NUVB
$1.33B
| $3.90 | $16 |
310%
upside
| Buy |
8 Mar ‘21
4 years ago |
|
20
89bio
ETNB
$1.32B
| $8.87 | $58 |
554%
upside
| Buy |
15 Sep ‘20
5 years ago |
|
21
Geron
GERN
$893M
| $1.40 | $3 |
114%
upside
| Buy |
3 Apr ‘20
5 years ago |
|